Value through InnovationJuly 23 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim press releases. To quickly find all press releases on a specific topic, please use the search.

Press Release Archive

back 1 2 3 4 5 6 7 8 9 10

Benefits and Safety of Pradaxa® (dabigatran etexilate mesylate) Repeatedly Confirmed


The Facts About Pradaxa® (dabigatran etexilate mesylate): Video Statement


Boehringer Ingelheim’s Investigational Therapy Nintedanib Receives FDA Breakthrough Therapy Designation

- For U.S. Media Only

NCLR Study Notes Barriers to Latino Health and Calls for Better Outreach and Prevention


Boehringer Ingelheim’s volasertib Phase II data including new overall survival results in older patients with acute myeloid leukemia published in Blood


U.S. FDA Accepts NDA Filing for Boehringer Ingelheim’s Investigational Nintedanib and Grants Priority Review Designation for the Treatment of Idiopathic Pulmonary Fibrosis

- For U.S. Media Only

CHMP Recommends Lilly and Boehringer Ingelheim’s Investigational New Insulin Glargine Product for Approval in the European Union

- For U.S. Media

Boehringer Ingelheim’s Investigational Antidote for Pradaxa® (dabigatran etexilate mesylate) Receives FDA Breakthrough Therapy Designation


Boehringer Ingelheim Announces Nintedanib Expanded Access Program (EAP) for Patients with Idiopathic Pulmonary Fibrosis

- For U.S. Media Only

Boehringer Ingelheim Initiates
RE-CIRCUIT™ Trial, Evaluating Pradaxa® (dabigatran etexilate mesylate) in NVAF Patients Undergoing Ablation

back 1 2 3 4 5 6 7 8 9 10